These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 1068296)
1. Chronic myelocytic leukemia and the myeloproliferative diseases during the child-bearing years. Miller JB J Reprod Med; 1976 Oct; 17(4):217-24. PubMed ID: 1068296 [TBL] [Abstract][Full Text] [Related]
2. [The treatment of myeloproliferative syndromes]. Maurice P Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995 [TBL] [Abstract][Full Text] [Related]
3. [Results of cytostatic and radiologic treatment of chronic myelocytic leukemia (analysis of 11 cases)]. Maurice PA Rev Med Suisse Romande; 1970 Jun; 90(6):521-32. PubMed ID: 5293581 [No Abstract] [Full Text] [Related]
4. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease. Litam PP; Landaw SA; Zamkoff KW Haematologia (Budap); 1994; 26(2):87-90. PubMed ID: 7890266 [TBL] [Abstract][Full Text] [Related]
5. The management of elderly patients with myeloproliferative disorders. Tura S Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340 [No Abstract] [Full Text] [Related]
7. Transplant decision-making strategies in the myeloproliferative disorders. Fruchtman SM Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880 [TBL] [Abstract][Full Text] [Related]
8. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy. Ryningen A; Apelseth T; Hausken T; Bruserud Ø Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601 [TBL] [Abstract][Full Text] [Related]
9. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584 [TBL] [Abstract][Full Text] [Related]
10. [Nosology and diagnosis of myeloproliferative syndrome]. Zittoun R; Bernadou A; Zittoun J; Fretault J; Bousser J Sem Hop; 1968 Jun; 44(31):2079-84. PubMed ID: 4300452 [No Abstract] [Full Text] [Related]
11. [Use of interferon in the treatment of chronic myeloproliferative disorders]. Robak T Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870 [TBL] [Abstract][Full Text] [Related]
12. Cytogenetic studies in the chronic myeloproliferative syndrome. Kiossoglou KA; Mitus WJ; Dameshek W Blood; 1966 Aug; 28(2):241-52. PubMed ID: 5222584 [No Abstract] [Full Text] [Related]
13. Treatment of myeloproliferative diseases. Sellei C Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101 [No Abstract] [Full Text] [Related]
14. Some uses of the continuous flow blood separator in the myeloproliferative syndrome. Bell R; Sullivan JR; Hurley TH; D'Apice AJ; Kincaid-Smith P Aust N Z J Med; 1978 Aug; 8(4):433-5. PubMed ID: 282861 [TBL] [Abstract][Full Text] [Related]
15. [Polycythemia vera and pregnancy: difficulties for diagnosis and treatment]. Deruelle P; Bouhassoun J; Trillot N; Jude B; Ducloy AS; Subtil D Gynecol Obstet Fertil; 2005 May; 33(5):331-7. PubMed ID: 15878688 [TBL] [Abstract][Full Text] [Related]
16. Thrombocytosis and thrombocythaemia. Murphy S Clin Haematol; 1983 Feb; 12(1):89-106. PubMed ID: 6340888 [No Abstract] [Full Text] [Related]
18. Diagnostic evaluation of the chronic myeloproliferative disorders. Spivak JL Isr Med Assoc J; 2002 Nov; 4(11):1028-31. PubMed ID: 12489498 [No Abstract] [Full Text] [Related]
19. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Nielsen I; Hasselbalch HC Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887 [TBL] [Abstract][Full Text] [Related]